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a  b  s  t  r  a  c  t
In  Africa  and  the  Arabian  Peninsula,  outbreaks  of  Rift  Valley  fever  (RVF)  are  characterized  by  abortions
in  gestating  animals  and  high  mortality  rates  among  domestic  ruminants.  An  immunization  program
using  a formalin-inactivated  vaccine  was  initiated  in Mozambique  in  2002  to  control  RVF  in  cattle.  In  this
intervention,  the  vaccine  must  be  transported  for more  than  a  week  within  the  country  before  it  can  be
administered  to  the  animals,  and  it is  practically  impossible  to maintain  low  storage  temperatures  during
that  time.  Here,  we  evaluated  the  inﬂuence  of  transportation  conditions  on  the  efﬁcacy  of  the  vaccine.
Sixty-three  previously  unvaccinated  and  RVF  virus  seronegative  cattle  were  divided  into  four  groups,
which  were  given  vaccine  that had been  stored  for  1 week  at 4 ◦C  (n  =  9,  group  A),  at 25 ◦C (n  =  8,  group
B),  or  alternating  between  4 and  25 ◦C (n  = 8, group  C), or  under  the  temperature  conditions  ordinarily
occurring  during  transportation  within  Mozambique  (n = 38,  group  D).  The  antibody  responses  induced
were  monitored  for 6–9  months  and  in  some  animals  up  to  21  months.  Two  immunizations  (3  weeks
apart)  with  the  formalin-inactivated  vaccine  induced  a long-lasting  neutralizing  antibody  response  that
was  still  detectable  up  to  21 months  later.  The  antibody  titers  in  the  animals  did  not differ  signiﬁcantly
between  the  temperature-assigned  vaccine  groups  A,  B,  and  C,  whereas  they  were  signiﬁcantly  higher  in
group  D.  These  results  show  that  the  formalin-inactivated  RVF  virus  vaccine  is  stable,  and,  importantly,
it  is  not  adversely  affected  by  the  variation  in  temperature  that  ordinarily  occurs  during  transport  within
Mozambique.. Introduction
The ﬁrst report of Rift Valley fever (RVF) among sheep in Kenya
as published in 1930 [1],  and since then the disease has become
idespread and endemic in Sub-Saharan Africa and Egypt, and later
lso in the Arabian Peninsula. The causative agent is the RVF virus
RVFV), which belongs to the genus Phlebovirus of the family Bun-
aviridae. The tripartite RNA genome (S, M,  and L segments) is
f negative or ambisense (S segment) polarity and encodes four
tructural proteins [2].  The highly immunogenic nucleocapsid (N)
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protein, which is encoded by the S segment, is increasingly being
used as the antigen of choice in serological assays [3,4]. The
membrane-associated Gn and Gc glycoproteins are encoded by the
M segment, and constitute the targets for virus-neutralizing anti-
bodies [5].
RVFV can infect a broad range of animal hosts, and outbreaks
of this disease often occur after heavy rains and ﬂooding have
generated favorable breeding conditions for the mosquito vectors
[6,7]. Viral infections in humans are usually manifested as mild,
self-limiting febrile illness, although in some cases there are more
severe symptoms, such as encephalitis, loss of vision, and hem-
orrhagic fever [8].  In animals infected with RVFV, spontaneous
abortions are frequently observed among gestating domestic rumi-
nants, and the mortality rate can reach 100% among newborn and
young individuals. RVF can be subclinical in older animals, but clin-
ical manifestations are also often severe in adults, with mortality
rates ranging from 10% to 70%, depending on the age, species, and
breed of the infected host [9].  Epizootics of RVF have resulted in
rigorous restrictions on the trade of animals and animal products,
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Fig. 1. Map of Mozambique and neighboring countries. The map  shows the capitalN. Lagerqvist et al. / Va
hich in turn have had a considerable socio-economic impact, not
nly on livestock keepers and food producers, but on the non-
gricultural sector as well [10].
Vaccination of livestock is the main measure used to control
VF in endemic areas. Many promising vaccine candidates are
nder evaluation [11–13],  although animals are currently being
mmunized with the live-attenuated Smithburn strain [14] or
ormalin-inactivated RVFV vaccines [15]. Unfortunately, the Smith-
urn strain has retained teratogenic characteristics, as noted in
tudies of pregnant cows and goats [16,17]. Compared to the live-
ttenuated strain, the formalin-inactivated vaccines are safer for
se in gestating animals, but they are also less immunogenic, and
nnual boosters are required to maintain protective immunity
18].
Outbreaks of RVF are reported regularly in several of the Sub-
aharan countries [19,20],  although the situation regarding this
isease in Mozambique is unclear. Strong evidence of RVFV trans-
ission in Mozambique was obtained as early as the 1960s [21],
nd this was conﬁrmed in the 1980s, when virus-speciﬁc antibod-
es were detected in 2% of pregnant women in the country [22].
urthermore, surveys of cattle in Zambezia Province (the central
egion of Mozambique) revealed high seropositivity, which led to
ntroduction of an immunization program in 2002 using a formalin-
nactivated vaccine [23].
In the present study, we investigated whether different storage
nd transport conditions affect the ability of formalin-inactivated
VFV vaccine to induce immune responses in cattle. For that
urpose, a commercial vaccine was stored under four different
onditions: at 4 ◦C, at 25 ◦C, alternating between 4 ◦C and 25 ◦C, or
ccording to the standard procedures stipulated by the Mozambi-
an Directorate of National Veterinary Services (see Section 2.3).
he antibody responses induced by the vaccine were monitored
y ELISA and plaque reduction neutralization tests (PRNTs) for 6–9
onths, and in some animals up to 21 months.
. Materials and methods
.1. Cells and viruses
Vero cells (ATCC no. CCL-81) were grown in Medium 199 (Gibco,
ife Technologies Corporation) supplemented with 100 U/mL peni-
illin, 100 g/mL streptomycin, and 5% heat-inactivated fetal
ovine serum (FBS). The cells were cultured at 37 ◦C in a humid-
ﬁed atmosphere containing 5% CO2. The RVFV strain ZH548 [24],
as propagated and titrated in Vero cells before being used in
mmunoﬂuorescence assays (IFAs) and PRNTs.
.2. Animals
The experimental procedures using animals were approved
y the Mozambican Board of Agriculture (ethical permission no.
55/DNSV/2008, Maputo). Thirty mixed breed cattle were raised
n a free-range feeding system in the Namaacha District, Maputo
rovince (Fig. 1), with the main diet based on grass and hay to
hich mineral salts and food supplements were added during the
ry season (March–August). These animals were divided into three
roups (designated A, B, and C) initially with 10 animals in each.
n additional 41 head of mixed-breed cattle (designated group
) were raised in the Alto Molocue District, Zambezia Province
Fig. 1), under conditions similar to those described for groups A–C,
ut without food supplements during the dry season. Two more
nimals were kept as negative controls in the Namaacha District,
aputo Province. None of the cattle had previously been vacci-
ated against RVFV. Characteristics of the animals are given in
able 1.city of Maputo (italics) and the provinces referred to in the article (bold capital let-
ters), as well as the city of Quelimane and the approximate locations of the Namaacha
and Alto Molocue Districts.
2.3. Vaccination and sample collection
In Maputo Province, vials containing formalin-inactivated RVFV
vaccine and aluminum hydroxide gel adjuvant (Onderstepoort Bio-
logical Products, batch no. 398) were stored for 1 week at 4 ◦C
(according to the manufacturer’s instructions), at 25 ◦C, or alternat-
ing between 4 and 25 ◦C (at 12-h intervals); thereafter, the vaccine
was  administered to the cattle in groups A, B, and C, respectively.
For group D in Zambezia Province, vaccine in vials was  transported
as currently stipulated by the Directorate of National Veterinary
Services before it was administered to the cattle. More precisely,
the vials were sent by air from Maputo to Quelimane and there-
after by car to the Alto Molocue District (Fig. 1), and the vaccine
was  subsequently given to the animals. The delivery took approx-
imately 1 week, and the vials were stored on ice or at 4 ◦C when
possible.
The animals were inoculated subcutaneously (16 G ½ in. needle)
lateral on the neck with 2 mL  of vaccine on day 0 and boosted on
day 21, according to the manufacturer’s instructions. Blood samples
were collected by venipuncture of the coccygeal vein on the day of
primary vaccination and thereafter for 287–630 days in groups A–C
and for 147 days in group D. Samples collected on days 45 and 48
were analyzed together and are referred to below as having been
taken on day 45. The blood samples were stored at 4 ◦C and later
centrifuged at 1500 × g to obtain sera, which were stored at −20 ◦C
pending analysis.2.4. Immunoﬂuorescence assay
Bovine serum samples diluted 1:40 in PBS were incubated with
monolayers of acetone-ﬁxed RVFV-infected Vero cells for 30 min  at
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Table 1
Characteristics of the cattle.
Group Province Animala Age (yr) Sex Weightb (kg) Sampling daysc
0 10 20 30 45 87 117 147 207 267 630
A (4 ◦C) Maputo A1 5 F 300 • • • • • • • • • • x
A2  4 F 260 • • • • • • • • • • •
A3 3 F 250 • • • • • • • • • • •
A5 8 F  400 • • • • • • • • • + +
A6 8  F 380 • • • • • • • • • • •
A7  8 F 380 • • • • • †
A8  8 F 360 • • • • • • • • x
A9  8 F 360 • • • • • • • • • • •
A10 8 F 300 • • • • • • • • • • •
B  (25 ◦C) Maputo B2 5 F 320 • • • • • • • • x
B4 4  F 300 • • • • • • • x
B5  5 M 340 • • • • • • • • • • •
B6  6 F 320 • • • • • • • • †
B7  6 F 300 • • • • • • + • • • •
B8  8 F 350 • • • • • • • • • • •
B9  8 F 250 • • • • • • • • • • x
B10  8 F 300 • • • • • • • • • • •
C  (4/25 ◦C) Maputo C1 8 M 280 • • • • • • • • • • •
C2 4 F 260 • • • • • • • • • • •
C3  6 F 340 • • • • • • • • • • •
C5  5 F 350 • • • • • • • • • • •
C6  5 F 300 • • • • • • • • • • •
C7  8 F 260 • • • • • • • • x
C8 8 F 250 • •  • • • • • • • • x
C10  8 F 400 • • • • • • • • • • •
D
(customary)d
Zambezia D1–D5 4–8 n/a n/a • • • • • • • •
D7  4–8 n/a n/a • • • • • • • +
D8–D29 4–8 n/a n/a • • • • • • • •
D30  4–8 n/a n/a • • • • • • • +
D31 4–8 n/a n/a • • • • • • • •
D33–D39 4–8 n/a n/a • • • • • • • •
D41 4–8 n/a n/a • • • • • • • •
Maputo ctrl1 6 F 300 • • • • • • • • • • •
ctrl2 5 F 300 • • • • • • • • • • •
a Animals A4, B1, B3, C4, C9, D6, D32, and D40 were excluded due to pre-exposure to Rift Valley fever virus.
b Weight was  estimated using a tape measure.
c Symbols indicate samples that could not be collected (+) or were not available because an animal died (†)  or was stolen or sold (x).
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tion titers were determined as the reciprocal of the highest serumVaccine was transported according to the customary procedures of the Mozamb
ot  available; ctrl, control.
7 ◦C. Next, the cells were washed 3 ×10 min  in 0.9% NaCl solution,
nd then ﬂuorescein-conjugated anti-bovine IgG antibody (Cappel,
P  Biomedicals Inc.) was added to a ﬁnal dilution of 1:50. There-
fter, the samples were incubated for 30 min  at 37 ◦C and then
ashed as above and mounted. The presence of anti-RVFV anti-
odies was determined by ﬂuorescence microscopy, and all serum
amples were analyzed in duplicate.
.5. ELISA
Full-length RVFV N protein (GenBank ID: AF134534) [25]
as produced from a prokaryotic expression vector pET14b
Novagen), and the recombinant N protein antigen was  puriﬁed
rom Escherichia coli cell lysates under native conditions using Ni-
TA agarose (Qiagen), as described elsewhere [26]. Indirect ELISA
as performed as reported by other authors [27] with these minor
hanges: the plates were coated with 3 g/mL recombinant N
rotein, and the antigen-antibody complexes were visualized by
se of peroxidase-conjugated anti-bovine IgG antibody (Jackson
mmunoResearch Laboratories) diluted 1:5000 and TMB substrate
3,3′,5,5′-tetramethylbenzidine, Sigma Aldrich). The reaction was
topped with 50 L of 1 M H2SO4, and the absorbance was mea-
ured at 450 nm.  The ELISA cut-off value was calculated using the
esults for 25 negative bovine sera and the Student t-distributionirectorate of National Veterinary Services (see Section 2.3). F, female; M,  male; n/a,
test with 99% conﬁdence intervals, as described in detail in the
literature [28]. Negative and positive bovine serum control sam-
ples were included in each plate. All samples were analyzed in
duplicate, and the titers were determined as the reciprocal of the
highest serum dilution that resulted in a reading above the cut-off
value.
2.6. Plaque reduction neutralization test
Heat-inactivated serum samples were serially diluted twofold in
Minimal Essential Medium (MEM,  Invitrogen) supplemented with
3% FBS, 100 U/mL penicillin, and 100 g/mL streptomycin, and then
incubated with 60 PFU of RVFV for 30 min  at 37 ◦C. Adsorption
of the serum-virus mixture to Vero cells was  allowed to proceed
for 1.5 h at 37 ◦C, and then the cells were washed, overlaid with
MEM  medium containing 0.75% carboxy methyl cellulose (Sigma
Aldrich), and incubated for 4 days at 37 ◦C under 5% CO2. The cells
were subsequently ﬁxed in 4% formaldehyde, and plaques were
visualized by counterstaining with crystal violet. The neutraliza-dilution that reduced virus infectivity by 80%. A titer of 20 was
considered positive after evaluating the assay using 25 negative
bovine sera. All procedures using viable RVFV were carried out in a
biosafety level 3 containment laboratory.
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Fig. 2. Percentage of seropositive cattle in each of the four vaccine groups. Formalin-inactivated RVFV vaccine was stored for 1 week at 4 ◦C, at 25 ◦C, alternating between 4 ◦C
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gainst  N protein (B). Arrows along the x-axis indicate immunization days. No data
.7. Statistical methods
Statistical correlations were analyzed using Spearman’s rank
est. The Kruskal–Wallis test was applied to achieve the initial
omparisons of the antibody responses exhibited by the four vac-
ination groups, and, if systematic variations were found, the
ann–Whitney U test was carried out to compare the vaccine-
nduced titers of the animals in the individual groups. Statistical
nalyses were performed with StatisticaTM 10 (StatSoft Inc.), and
raphs were visualized using GraphPadTM Prism 4 (GraphPad Soft-
are Inc.).
. Results and discussion
The sporadic reports of outbreaks of RVF in neighboring coun-
ries illustrate that there is a continuous risk to Mozambique,
ecause it is one of the most frequently ﬂooded countries in the
outhern part of Africa [29]. Notably, Mozambique has been spared
rom RVF in humans or livestock, with the exception of the out-
reaks that occurred in 1969 and 1994, which caused abortions and
eaths in cattle and water buffalo [9,21,30]. Nevertheless, surveil-
ance of cattle in Zambezia Province (Fig. 1) in 1996 and 2001
evealed seroprevalence of 37% and 53%, respectively [23]. Accord-
ngly, in 2002, a vaccination program was initiated in districts in
hat province to prevent RVFV infections in cattle. Inasmuch as
here was considered to be a high risk of RVF after the ﬂooding that
ad affected the southern part of the country in 2000 and the central
egion in 2001, the vaccination program was extended in late 2002
o include the provinces of Gaza and Manica (Fig. 1) [31]. However,
fter 2004, vaccination of livestock was once again limited to only few districts in Zambezia Province.
The antibody status of the cattle to be used in our study was
nitially unknown, and thus, to start with, we assessed RVFV
eronegativity by IFA, and the results were later conﬁrmed by PRNTnistered twice (3-week interval, day 0 and day 21) to animals in groups designated
the indicated days by plaque reduction neutralization tests (A) and indirect ELISA
available for the animals in group D on the days marked with a superscript ‘x’.
(data not shown). A seropositivity rate of 7% was found among the
41 animals kept in Zambezia Province (group D), which was a rela-
tively low level compared to the sero-surveillance data previously
recorded in that province [23]. On the other hand, 17% of the 30
animals in Maputo Province (groups A, B, and C) were positive for
anti-RVFV antibodies, which was  a surprisingly high rate. It was
in this region that the last small outbreaks of RVF in cattle were
reported in 1969 [21]. These results indicate that RVFV is circulat-
ing in Maputo Province, but it is either not causing manifest clinical
disease or not being diagnosed.
Cattle that were found to have elevated RVFV antibody titers
before the primary immunization were not included in the study
(Table 1). Furthermore, none of the negative control animals
showed seroconversion over the experimental period, analyzed as
the presence of antibodies against the N protein or by virus neu-
tralization tests (data not shown).
The ability of the bovine antisera to neutralize RVFV in vitro
was  analyzed by PRNT. Our data show that the majority of the
animals in all four groups (78%, 88%, 88%, and 74% in A, B, C,
and D, respectively) seroconverted rapidly in response to the
primary vaccination (Fig. 2A). After the second immunization,
all animals in groups A, B, and C had elevated PRNT titers (≥80)
(Figs. 2A and 3A). However, four of the animals in group D (n = 38)
failed to seroconvert 9 days after receiving the booster dose;
three of those four seroconverted by day 45, whereas the fourth
animal did not develop detectable anti-N protein or neutralizing
antibodies over the entire experimental period. In general, neu-
tralizing antibody titers showed small peaks on days 30–45 and
thereafter declined relatively rapidly in groups A–C but not in
group D (Fig. 3A). Interestingly, the antibody titers of the cattle
in group D peaked on day 45 and remained high until day 147
(Fig. 3A). Furthermore, two-thirds of the animals in groups A, B,
and C still had detectable levels of neutralizing antibodies 267 days
after vaccination (Fig. 2A). It can be mentioned that comparable
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Fig. 3. Bar charts showing the median antibody titers in the vaccinated cattle. Four groups of cattle were immunized with formalin-inactivated RVFV vaccine that had been
stored at 4 ◦C (group A), 25 ◦C (group B), or alternating between 4 ◦C and 25 ◦C (group C), or had been transported within Mozambique according to the practice stipulated in
that  country. Two doses were administered (primary vaccination on day 0 and booster on day 21), and the vaccine-induced neutralizing antibody responses (A) and anti-N
antibody responses (B) were determined by a plaque reduction neutralization test and indirect ELISA, respectively. Serum samples were collected from the animals on the
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ong-lasting titers of neutralizing antibodies had previously been
bserved by other researchers in a study using a comparable
ormalin-inactivated RVFV vaccine [32]. We  also noted that 73%
f the animals in our investigation still had neutralizing antibody
iters in the range of 40–320 (median 40) (Figs. 2A and 3A)  630 days
fter the initial vaccination. The extent and duration of the pro-
ective immunity induced by formalin-inactivated RVFV vaccines
re considered to be “short termed”, and consequently annual
ooster immunizations are given to cattle to maintain immunity.
owever, our observations indicate that the neutralizing antibody
esponses induced by the formalin-inactivated RVFV vaccines may
e more robust and long-lasting than expected.
Indirect ELISA based on recombinant N protein has the poten-
ial for use in routine diagnostics and epidemiological studies of
VF [33]. Therefore, we decided to monitor the levels of anti-N-
rotein antibody in serum samples of the vaccinated cattle. Anti-N
ntibody responses were detected in about one-third of the animals
fter the primary vaccination, and nearly 80% of the animals were
eropositive nine days after the booster immunization, regardless
f treatment group (Fig. 2B). In contrast to the neutralizing antibody
esponses, circulating anti-N antibodies could only be detected for
 short period of time. On day 147 after the primary immuniza-
ion (126 days after booster), the majority (74%) of the animals in
roups A–C were negative for antibodies against the recombinant
 protein (Fig. 2B), whereas such seronegativity was  observed in
nly 14% of the animals in group D at that time (Fig. 2B). By the
nd of the study period, all but four of the investigated animalst “x”. Arrows along the x-axis indicate immunization days. Brackets and asterisks
 **p ≤ 0.01; ***p ≤ 0.001).
had exhibited anti-N antibody responses after the two immuniza-
tions.
We  also noted that, after receiving the immunizations, the ani-
mals that had low vaccination anti-N protein titers (≤100) showed
neutralizing antibody titers similar to those seen in the animals that
had stronger vaccination anti-N antibody responses. The ELISA used
in this study measures antibodies directed toward the N protein,
while the PRNT mainly measures neutralizing antibodies directed
toward the glycoproteins. Thus the level of anti-N antibodies may
not be relevant as an indicator of vaccination status. It is possi-
ble that the lack of a relationship between anti-N and neutralizing
antibody titers (group A, Spearman’s rank test) can be explained
by differences in assay sensitivity, however our analyses indicate
that serology based on the response to N protein may  not be the
method of choice for evaluating the efﬁcacy of immunization with
formalin-inactivated RVFV vaccines.
Formalin-inactivated vaccines are in general more stable than
attenuated vaccines [34]. Efforts have been made to increase the
stability of formalin-inactivated RVFV vaccines even further by
lyophilization [35], but the preparations used in our study were
in ﬂuid form, and, to our knowledge, no evaluations have been
performed to determine the efﬁcacy of that type of formalin-
inactivated RVFV formula after storage or transportation at ambient
temperatures.
In our investigation, analysis of the impact of the differ-
ent vaccine storage conditions on neutralizing antibody titers
measured after immunization (Fig. 3A) revealed no signiﬁcant
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ifferences between the four experimental groups on days 10,
0, and 45, or between groups A, B, and C on days 207, 267
nd 630 (Kruskal–Wallis test). However, the neutralizing antibody
esponses differed signiﬁcantly between the four groups on days
0, 87, 117, and 147 after the ﬁrst vaccination (p = 0.023, 0.004,
.000, and 0.001, respectively; Kruskal–Wallis test). Accordingly,
he individual groups of animals were subjected to further analysis
sing the Mann–Whitney U test. On day 30, neutralizing antibody
iters were higher in group B than in group D, which might be
xplained by the earlier antibody peak (Fig. 3A). However, from
ay 45 and onward, the results were reversed, that is, the titers in
roup D were elevated (albeit only slightly) compared to those in
roup B (Fig. 3A). Furthermore, somewhat surprisingly, the anti-
ody titers observed on days 87, 117, and 147 were higher in group
 than in groups A and C (Fig. 3A).
A similar pattern was observed concerning the levels of anti-N
rotein antibody (Fig. 3B), which differed between the groups on
ays 10, 20, 87, 117, and 147 (p = 0.035, 0.006, 0.001, 0.000, and
.000, respectively; Kruskal–Wallis). Comparisons of the individ-
al groups regarding the results for the indicated sampling days
evealed that the titers measured in group D were higher than those
n groups A and C, and also higher than those in group B on some of
he days (Mann–Whitney U test) (Fig. 3B). As for the neutralizing
ntibody titers, the anti-N protein antibody responses did not dif-
er signiﬁcantly between groups A, B, and C on days 207, 267, and
30 after vaccination. Several unrelated factors, such as the breed
nd the nutritional status of the animals may  inﬂuence vaccine-
nduced immune responses [36], which might explain the higher
ntibody titers we observed in the animals in group D. Moreover,
n general, the vaccine from vials stored at the recommended tem-
erature (4 ◦C) induced equivalent or slightly lower antibody levels
ompared to the vaccine stored at ambient temperatures (alternat-
ng between 4 and 25 ◦C) or at 25 ◦C. These effects were noted in
attle belonging to the same herd (groups A, B and C), which sug-
ests that storage for 1 week under adverse conditions does not
mpair the ability of the vaccine to induce the humoral antibody
esponses.
In summary, of the animals included in this study, only one
ailed to acquire a detectable antibody response after two vacci-
ations. Furthermore, the antibody responses were still detectable
p to 21 months after the immunizations. Based on the data
resented here, we conclude that the storage and transport con-
itions used in Mozambique do not have an adverse effect on
he antibody responses induced by the formalin-inactivated RVFV
accine.
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